The main risk is still delivery, not demand. Core Scientific must convert announced and contracted power into billable
MW quickly enough to outrun debt drag, customer concentration, and self-build competition. If the company hits the 2026-2027 campus milestones and signs non-
CoreWeave customers, the asset base can
rerate meaningfully; if not, equity upside can be absorbed by
capex, financing, and multiple compression.